Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV

Mauas, Romina; Ureña, Analia; Cecchini, Diego; Strada, Maria L; Arietti, Soledad; Cassetti, Isabel; Nogueira, Nicholas Fonseca; Salazar, Ana S.; Rodriguez, Violeta J.; Jones, Deborah L.; Alcaide, María L.

doi:10.1097/qad.0000000000003483

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two main types are adenoviral vectors [118] and lentiviral vectors [119]. Adenoviral vectors are derived from adenoviruses [118], while lentiviral vectors are derived from lentiviruses, such as the human immunodeficiency virus (HIV) [119,120]. These vectors have been engineered to be replication-deficient and non-pathogenic, making them safe for therapeutic use [116].…”

Section: Viral Vectors In Drug Delivery Systems Formentioning

confidence: 99%

“…For example, Polysorbate 80 and Polyethylene glycol (PEG) are essential components in some COVID-19 vaccine formulations, each playing a unique role in vaccine stability and efficacy [8]. Polysorbate 80 is utilized in COVID-19 vaccines of AstraZeneca (ChAdOx1-S) [120] and Janssen (Ad26.COV2-S) to stabilize the aqueous components of the vaccine [8]. These vaccines employ a viral vector approach, encoding the SARS-CoV-2 spike glycoprotein [8].…”

Section: Vaccine Delivery Hydrogelsmentioning

confidence: 99%

See 1 more Smart Citation

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Hoc Thang,

Van Phuc,

Nhi

et al. 2024

Express Polym. Lett.

View full text Add to dashboard Cite

The COVID-19 pandemic has presented an array of challenges and given rise to a spectrum of diseases and health issues [1]. Foremost among the challenges of the pandemic is the swift transmission of the SARS-CoV-2 virus [2]. Strategies to curb transmission encompass extensive vaccination campaigns [3], the implementation of public health measures like mask-wearing [4] and social distancing [4], and the promotion of hygiene practices such as frequent handwashing [5]. The SARS-CoV-2 virus, which causes COVID-19, primarily targets the respiratory system [6]. However, it can also precipitate various complications and impact other organs and bodily systems [7]. COVID-19, an abbreviation for Coronavirus Disease 2019, is the ailment brought about by the SARS-CoV-2 virus [8]. It manifests as a broad spectrum of symptoms, spanning from mild to severe respiratory ailments [9]. Common symptoms include fever, cough, shortness of breath, fatigue, loss of taste or smell, and body aches [10]. In severe instances, it can progress to pneumonia and acute

show abstract

Section: Viral Vectors In Drug Delivery Systems Formentioning

confidence: 99%

Section: Vaccine Delivery Hydrogelsmentioning

confidence: 99%

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Hoc Thang,

Van Phuc,

Nhi

et al. 2024

Express Polym. Lett.

View full text Add to dashboard Cite

show abstract

SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis

Søndergaard,

Thavarajah,

Churchill Henson

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

BackgroundPrevious publications on the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines in people living with HIV (PLWH) have reported inconsistent results. Additionally, a meta‐analysis investigating the immunogenicity in PLWH after the third SARS‐CoV‐2 vaccine dose is lacking. In this article we aim to provide a systematic review and a meta‐analysis studying the immunogenicity of SARS‐CoV‐2 vaccines in PLWH and to identify potential drivers for antibody response in PLWH.MethodsWe used three databases (PubMed, Embase and Web of Science) to conduct our review. Studies with information on numbers of PLWH producing immunoglobulin G (IgG) antibodies or neutralizing antibodies were included.ResultsThe meta‐analysis included 59 studies and illustrated a pooled serological response of 87.09% in the 10 343 PLWH after they received a SARS‐CoV‐2 vaccine. High CD4 T‐cell counts and low viral load indicated that the study populations had HIV that was well treated, despite varying in location. The pooled effect increased to 91.62% for 8053 PLWH when excluding studies that used inactivated vaccines (BBIBP‐CorV and CoronaVac). For the third vaccine dose, the pooled effect was 92.35% for 1974 PLWH. Additionally, weighted linear regression models demonstrated weak relationships between CD4 T‐cell count, percentages of people with undetectable HIV load, and age compared with the percentages of PLWH producing a serological response. However, more research is needed to determine the effect of those factors on SARS‐CoV‐2 vaccine immunogenicity in PLWH.ConclusionSARS‐CoV‐2 vaccines show a favourable effect on immunogenicity in PLWH. However, the results are not ideal. This meta‐analysis suggests that a third SARS‐CoV‐2 vaccine dose and good HIV treatment procedures are vital to induce a good immunogenicity in PLWH.

show abstract

Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV

Cited by 2 publications

References 22 publications

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis

Contact Info

Product

Resources

About